Communiqués Cartesian Therapeutics, Inc.

Actions

RNAC

US8162123025

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/07/2026			Varia. 5j.	Varia. 1 janv.
7,790 ^USD	-1,14%		-4,77%	+8,04%

09/06	Cartesian Therapeutics signe un accord de licence avec WestGene pour le développement de thérapies contre les maladies auto-immunes	MT
26/05	Cartesian Therapeutics, Inc. annonce des changements au sein de sa direction	CI

Communiqués

02/07	Cartesian Therapeutics Announces New Employment Inducement Grants	AQ
12/06	Cartesian Therapeutics Announces New Employment Inducement Grant	AQ
09/06	Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases	AQ
26/05	Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027	AQ
12/05	Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ	AQ
04/05	Cartesian Therapeutics Announces New Employment Inducement Grants	AQ
30/04	Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
02/04	Cartesian Therapeutics Announces New Employment Inducement Grants	AQ
12/03	Efficacy and safety of Descartes-08 in AChR+ generalized myasthenia gravis: subgroup analysis of a Phase 2b randomized, placebo-controlled trial	PU
09/03	Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update	AQ
23/02	Cartesian Therapeutics to Participate in Upcoming Investor Conferences	AQ
03/02	Cartesian Therapeutics Announces New Employment Inducement Grants	AQ
12/01	Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook	AQ
09/01	Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook	AQ
06/01	Cartesian Therapeutics Announces New Employment Inducement Grants	AQ
18/12	Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors	AQ
13/11	Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis	AQ
06/11	Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
30/10/25	Cartesian Therapeutics Announces New Employment Inducement Grants	AQ
30/10/25	Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors	AQ
06/10/25	Cartesian Therapeutics Announces New Employment Inducement Grant	AQ
03/10/25	Cartesian Therapeutics Announces New Employment Inducement Grant	AQ
26/09/25	Efficacy and safety of autologous BCMA‑directed mRNA CAR T-cell therapy in generalized myasthenia gravis: Results from a phase 2b randomized placebo-controlled trial	PU
28/08/25	Cartesian Therapeutics to Participate in Upcoming Investor Conferences	AQ
07/08/25	Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update	AQ